Bristol Myers Squibb

News

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).

Digital

AI tissue analysis enables rapid discovery of drug candidate...

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient gr

News

BMS' plan to move Opdivo into adjuvant RCC gets knocked back

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), th

News

Opdualag off to a flying start, says BMS CEO

Bristol-Myers Squibb's new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks but is already off to a "great start", according to chief executiv

News

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its

News

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.

BMS adds to IBD pipeline with $1.9bn GentiBio deal

AI tissue analysis enables rapid discovery of drug candidate...

BMS' plan to move Opdivo into adjuvant RCC gets knocked back

Opdualag off to a flying start, says BMS CEO

Roche's fast-growing eye drug Vabysmo set for EU approval

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Bristol Myers Squibb

Editor's Picks